Simtriyo: the new ADHD medication that works on three brain pathways

Yes, I have heard of it, and it is worth your attention. On July 24, 2026, the FDA approved a brand new ADHD medication called centanafadine, sold under the brand name Simtriyo and made by Otsuka. It is the first medication ever approved that blocks the reuptake of three brain chemicals at once: norepinephrine, dopamine, and serotonin. Scientists call this class NDSRI, short for norepinephrine dopamine serotonin reuptake inhibitor.

Why is that a big deal? Every ADHD medication we have today works through one or two pathways. Classic stimulants mainly raise dopamine and norepinephrine. Atomoxetine raises norepinephrine. Viloxazine touches norepinephrine and serotonin. Simtriyo is the first to target all three at once, which may matter because ADHD is not only about focus. It also involves motivation, impulse control, and emotional regulation, and serotonin plays a real role in that last piece. One important correction: early news stories called this a nonstimulant. The approved label disagrees. It classifies Simtriyo as a central nervous system stimulant, and it carries a boxed warning for abuse, misuse, and addiction. So it is a new kind of stimulant, not a nonstimulant, and that distinction changes how it will be prescribed.

How does it work in plain language? Brain cells communicate by releasing chemical messengers into the gaps between them, then vacuuming the leftovers back up. That vacuum step is called reuptake. Simtriyo blocks the vacuum for norepinephrine, dopamine, and serotonin, leaving more of each messenger available in the circuits that govern attention and behavior. It comes as a once daily extended release capsule.

What did the trials actually show? The approval rested on four large phase 3 trials covering children, teens, and adults. In two adult trials, both the 200 mg and 400 mg daily doses beat placebo on standard ADHD symptom scores. In teens ages 13 to 17, the higher dose worked, and improvement showed up as early as week one, which is fast. A separate study in adults who had both ADHD and anxiety also met its main goal, improving ADHD symptoms and anxiety scores together. That last finding matters because roughly a third of people with ADHD also live with anxiety.

One more piece of context is worth adding, because it shapes who this drug fits best. A pooled analysis of the phase 3 program found an overall effect size around 0.37, which is real but modest, roughly a third to half of what standard stimulants typically show in trials. The trade off appears in tolerability, particularly less insomnia, and in the emotional regulation and executive function signals that later analyses picked up. That profile points toward patients whose anxiety, sleep, or substance use history makes classic stimulants a poor fit, rather than a reason to switch when a current medication is already working well.

What are the side effects? They differ a bit by age. In children ages 6 to 12, the most common were rash and decreased appetite. In teens, decreased appetite, nausea, rash, headache, and stomach pain. In adults, headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea. Most were mild to moderate. The label carries two boxed warnings, the strongest kind. The first is for suicidal thoughts and behaviors in children ages 6 to 12, where treated children had higher rates than those on placebo. Every pediatric patient must be watched closely for this. The second is the stimulant abuse and misuse warning, which means prescribers must assess risk before starting and keep monitoring during treatment.

What about sexual side effects? Fair question, since many psychiatric medications affect libido or performance. In the trials so far, sexual dysfunction did not appear among the commonly reported side effects. That is encouraging, but this drug is brand new, and uncommon effects only surface once thousands of people use a medication in everyday practice. I will update this post as longer term data arrive.

What about weight, heart rate, and blood pressure? Decreased appetite was one of the most common side effects, so some weight loss is possible, and children need growth monitoring, which is standard for stimulant class medications. Heart rate and blood pressure should be checked before starting and during treatment. It must not be combined with MAO inhibitor antidepressants, and it is not for anyone with a history of pheochromocytoma, a rare adrenal tumor.

How much will it cost if insurance does not cover it? Honest answer: nobody knows yet. Otsuka has not published a price, and no pharmacy can stock the drug until the DEA finishes its scheduling review. It will launch as brand only, and brand only ADHD medications typically cost several hundred dollars per month cash. Once it launches, expect insurers to require prior authorization and proof that cheaper generics were tried first. I will update this post with real numbers the moment they are published.

Can it be prescribed right now? Not yet. The FDA has approved it, but federal law requires the DEA to assign a controlled substance schedule before any pharmacy can dispense it, and that review is still pending as of early October 2026. Otsuka expects it to be available later this year. So the honest timeline is simple: approved, but not yet prescribable. If you are doing well on your current medication, do not stop or change anything while waiting. When it does launch, the most natural candidates will be people who have not responded well to existing options, or who might benefit from the serotonin piece, for example ADHD with strong emotional dysregulation or coexisting anxiety.

Bottom line: this is the first genuinely new mechanism for ADHD in years, and the trial data behind it are solid. The stimulant label and the boxed warnings mean it deserves respect, not fear. I am watching the DEA decision and the launch closely, and I will keep this page updated. If you want to talk about whether it might fit your situation once it is available, that conversation is exactly what a consultation is for.

Anthony

Sources: Adler LA et al., Journal of Clinical Psychopharmacology (2022), two phase 3 trials of centanafadine in adults, PMID 35652746. Ward CL et al., Journal of the American Academy of Child and Adolescent Psychiatry (2026), phase 3 trial of centanafadine in adolescents, PMID 40619095. Otsuka Pharmaceutical news release on FDA approval of Simtriyo (centanafadine), July 24, 2026. Pharmacy Times, Psychiatric Pharmacy Pulse (2026), pooled phase 3 effect size summary. Psychology Today (2026), comparison of new ADHD medications.